Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Pharmaceutical

Daiichi Sankyo

Ken Keller

Amy Todd Klug

Lerryn Trzcinski

Brian Hauser

James Felix

Rich Jones

Mila Tartakovsky

Fussy Tracy

Kevin R Forrest

Matt Siegel

Michael Grosso

Barry Fortner

Daniel Switzer

Dale E. Shuster

Stu Mackey

Scott Cleve

Michele Schmidt

Barbara Tantillo Rn Bsn

Raquel Coca Lopez

Simon King

Kara Reheis

Hayes Williams

Ken Takeshita

The Oncology Research and Development Team at Daiichi Sankyo is dedicated to advancing cancer therapies through innovative research and clinical development. The team focuses on discovering and developing new oncology drugs, managing clinical trials, ensuring regulatory compliance, and enhancing patient safety. They work collaboratively to translate scientific discoveries into effective treatments, with a strong emphasis on precision medicine and strategic alliances for global impact.

Oncology Research and Development Team

Clinical Research and Development

Clinical Operations

Oncology Research and Development Team

About

Team members

Other teams at Daiichi Sankyo

Clinical Research and Development

Clinical Operations